Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals' views

被引:10
|
作者
Wang, Yishen [1 ]
Bajorek, Beata [1 ,2 ]
机构
[1] Univ Technol Sydney, Grad Sch Hlth Pharm, Sydney, NSW 2007, Australia
[2] Royal N Shore Hosp, Dept Pharm, Sydney, NSW, Australia
关键词
Atrial fibrillation; Australia; Decision making; DOACs; Health professionals; Novel oral anticoagulant; Stroke prevention; Warfarin; HEART RHYTHM ASSOCIATION; ORAL ANTICOAGULANTS; EUROPEAN-SOCIETY; OLDER PATIENTS; MANAGEMENT; WARFARIN; THERAPY; RISK; PRESCRIPTION; GUIDELINES;
D O I
10.1007/s11096-016-0329-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background For stroke prevention in patients with atrial fibrillation (AF), the decision-making around antithrombotic therapy has been complicated by older age, multiple comorbidities, polypharmacy and the different pharmacological properties of warfarin and the nonvitamin K antagonist oral anticoagulants (NOACs). The complexity of decision-making has been associated with a reluctance by health professionals to use antithrombotic therapy, leading to poor clinical outcomes. In order to improve stroke prevention in patients with AF, the contemporary perspectives of health professionals on the decision-making around antithrombotic therapy needs exploration. Objective To elicit emerging themes describing health professionals' perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Setting Sydney metropolitan area of New South Wales, Australia. Method A qualitative study based on face-to-face interviews was conducted from August to October 2014. Seven pharmacists, seven specialists, six general practitioners and six nurses practising in the Sydney metropolitan area and managing antithrombotic therapy for AF were interviewed until theme saturation was achieved in each subgroup. Interview transcripts were analysed using manual inductive coding. Main outcome measure Emerging themes describing health professionals' perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Results Three overarching themes emerged. (1) Comprehensive assessment is necessary for decision-making but is not always implemented. Health professionals mostly focused on stroke risk assessment, not on the bleeding risk and medication safety issues. (2) Health professionals from different disciplines have different preferences for antithrombotic therapies. Although the majority of health professionals considered warfarin as the first-line therapy, NOACs were preferred by neurologists and haematologists. (3) Health professionals focused on different aspects of the decision making process: GPs and specialists were concerned about the appropriate prescription of antithrombotics, while pharmacists and nurses focused on daily medication management by patients. Conclusion The decision-making process appears to be partially preference based rather than systematic, and health professionals from various disciplines focus on different parts of the decision-making process.
引用
收藏
页码:985 / 995
页数:11
相关论文
共 50 条
  • [31] Novel anticoagulants for stroke prevention in atrial fibrillation
    Baumhaekel, M.
    Schirmer, S. H.
    Boehm, M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (46) : 2304 - 2308
  • [32] A Pharmacoeconomic Perspective on Stroke Prevention in Atrial Fibrillation
    Fendrick, A. Mark
    AMERICAN JOURNAL OF MANAGED CARE, 2010, 16 (10) : S284 - S290
  • [33] New Frontiers for Stroke Prevention in Atrial Fibrillation
    Prasad, Vinayak
    Kaplan, Rachel M.
    Passman, Rod S.
    CEREBROVASCULAR DISEASES, 2012, 33 (03) : 199 - 208
  • [34] RIVAROXABAN IN PREVENTION OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION
    Simonyi Gabor
    Medvegy Mihaly
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2012, 65 (11-12): : 365 - 368
  • [35] Dabigatran for the prevention of stroke in patients with atrial fibrillation
    Diener, Hans-Christoph
    Weber, Ralph
    Weimar, Christian
    Frank, Benedikt
    Kirchhof, Paulus
    PSYCHOPHARMAKOTHERAPIE, 2011, 18 (04): : 156 - +
  • [36] Left Atrial Appendage Devices for Stroke Prevention in Atrial Fibrillation
    Hussain, Sarah K.
    Malhotra, Rohit
    DiMarco, John P.
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2014, 7 (04) : 458 - 464
  • [37] Shared decision-making tool for thromboprophylaxis in atrial fibrillation - A feasibility study
    Eckman, Mark H.
    Costea, Alexandru
    Attari, Mehran
    Munjal, Jitender
    Wise, Ruth E.
    Knochelmann, Carol
    Flaherty, Matthew L.
    Baker, Pete
    Ireton, Robert
    Harnett, Brett M.
    Leonard, Anthony C.
    Steen, Dylan
    Rose, Adam
    Kues, John
    AMERICAN HEART JOURNAL, 2018, 199 : 13 - 21
  • [38] Oral Anticoagulation in Atrial Fibrillation: Development and Evaluation of a Mobile Health Application to Support Shared Decision-Making
    Stephan, Laura Siga
    Almeida, Eduardo Dytz
    Guimaraes, Raphael Boesche
    Ley, Antonio Gaudie
    Mathias, Rodrigo Goncalves
    Assis, Maria Valeria
    Luz Leiria, Tiago Luiz
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2018, 110 (01) : 7 - 14
  • [39] Factors Associated With Patient Engagement in Shared Decision-Making for Stroke Prevention Among Older Adults with Atrial Fibrillation
    Mehawej, Jordy
    Saczysnki, Jane
    Abu, Hawa O.
    Gagnier, Marc
    Bamgbade, Benita
    Lessard, Darleen
    Trymbulak, Katherine
    Saliba, Connor
    Kiefe, Catarina
    Goldberg, Robert
    McManus, David
    CANADIAN GERIATRICS JOURNAL, 2021, 24 (03) : 174 - 183
  • [40] Pilot of a Computerised Antithrombotic Risk Assessment Tool Version 2 (CARATV2.0) for stroke prevention in atrial fibrillation
    Wang, Yishen
    Bajorek, Beata
    CARDIOLOGY JOURNAL, 2017, 24 (02) : 176 - 187